Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Antibe Therapeutics Inc    ATE   CA0370251039

ANTIBE THERAPEUTICS INC

(ATE)
My previous session
Most popular
  Report  
Delayed Quote. Delayed TSX VENTURE EXCHANGE - 03/18 03:59:47 pm
0.28 CAD   +3.70%
02/18ANTIBE THERAPEUTICS : Reports Q3 2019 Interim Financial and Operating Results
AQ
02/04ANTIBE THERAPEUTICS : IIROC Trading Resumption - ATE
AQ
02/04ANTIBE THERAPEUTICS : IIROC Trading Halt - ATE
AQ
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tsx Venture Exchange
03/12/2019 03/13/2019 03/14/2019 03/15/2019 03/18/2019 Date
0.295(c) 0.29(c) 0.28(c) 0.27(c) 0.28(c) Last
202 238 545 782 782 390 400 667 1 046 485 Volume
-1.67% -1.69% -3.45% -3.57% +3.70% Change
More quotes
Financials (CAD)
Sales 2019 9,11 M
EBIT 2019 -7,60 M
Net income 2019 -7,73 M
Debt 2019 -
Yield 2019 -
Sales 2020 9,84 M
EBIT 2020 -5,20 M
Net income 2020 -7,90 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 7,48x
Capi. / Sales2020 6,92x
Capitalization 68,1 M
More Financials
Company
Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and... 
More about the company
Latest news on ANTIBE THERAPEUTICS INC
02/18ANTIBE THERAPEUTICS : Reports Q3 2019 Interim Financial and Operating Results
AQ
02/04ANTIBE THERAPEUTICS : IIROC Trading Resumption - ATE
AQ
02/04ANTIBE THERAPEUTICS : IIROC Trading Halt - ATE
AQ
01/22ANTIBE THERAPEUTICS : Receives Approval to Initiate Part Two of Phase 2B Dose-Ra..
AQ
2018ANTIBE THERAPEUTICS : Announces Successful Completion of Part One of Phase 2B Do..
BU
2018KWANGDONG PHARMACEUTICAL : licenses Canadian companys nonsteroidal anti-inflamma..
AQ
2018ANTIBE THERAPEUTICS : Announces Strategic Licensing Deal for Lead Drug in South ..
AQ
2018ANTIBE THERAPEUTICS : Enters Strategic Licensing Deal for Lead Drug in South Kor..
AQ
2018ANTIBE THERAPEUTICS : Reports Q1 2019 Interim Financial and Operating Results
AQ
2018ANTIBE THERAPEUTICS : Completes Share Issuance in Connection with Citagenix Cred..
AQ
More news
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart ANTIBE THERAPEUTICS INC
Duration : Period :
Antibe Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 1,40  CAD
Spread / Average Target 400%
EPS Revisions
Managers
NameTitle
Daniel Legault President, Chief Executive Officer & Director
Walter M. MacNee Chairman
Alain Wilson Chief Financial Officer
John Lawrence Wallace Director & Chief Scientific Officer
Roderick J. Flower Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTIBE THERAPEUTICS INC-9.68%51
GILEAD SCIENCES4.92%83 712
VERTEX PHARMACEUTICALS13.51%48 087
REGENERON PHARMACEUTICALS10.97%44 500
GENMAB5.15%10 483
SAREPTA THERAPEUTICS INC17.62%9 457